<- Back to digest

JBJS - 2026-10-15 - Journal Article

Molecular Mechanisms of Osteoarthritis: A Review and Opportunities for Novel Therapeutics.

Meininger AK, Baydoun HE

systematic reviewLOE Vn = N/AN/A

Topics

basic science
PMID: 42879521DOI: 10.2106/JBJS.26.00446View on PubMed ->

Key Takeaway

NF-κB and MAPK dysregulation, chondrocyte senescence, and impaired autophagy are identified as the central molecular drivers of OA, with Wnt inhibitors and FGF-18 analogs representing the most clinically advanced disease-modifying candidates.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This narrative review synthesizes current molecular mechanisms underlying OA pathogenesis and evaluates emerging therapeutic targets. It identifies chondrocyte phenotypic shift toward catabolism, senescent cell accumulation, and adaptive immune involvement as key disease drivers. Translational candidates including Wnt pathway inhibitors, FGF-18 analogs (sprifermin), senolytics, gene therapy, and allogeneic MSC implantation are reviewed against a backdrop of mixed clinical trial results.

Key Limitation

The review does not stratify therapeutic candidates by OA endotype or disease stage, making it impossible to determine which molecular targets are relevant to which patient subpopulations — the precision medicine framework it advocates is described conceptually without operational criteria.

Original Abstract

➢ Osteoarthritis (OA) represents a biologically dynamic disease characterized by progressive failure of cartilage homeostasis through interconnected molecular mechanisms. Chondrocytes shift from an anabolic to a catabolic phenotype, marked by increased matrix metalloproteinase activity, while the synthetic capacity of articular cartilage diminishes.➢ Key signaling cascades including NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase) become dysregulated, driving matrix degradation. Declining autophagy impairs cellular quality control while senescent cells accumulate, releasing inflammatory mediators that amplify tissue damage. The immune response extends beyond macrophage polarization to involve adaptive immune cells, including T cell subsets that sustain chronic synovial inflammation.➢ Emerging disease-modifying strategies-including Wnt pathway inhibitors, FGF (fibroblast growth factor) 18 analogs, senolytic agents, gene therapy approaches, and allogeneic MSC (mesenchymal stem cell) implantation-offer the first genuine prospects for altering the natural history of this disease. However, translational challenges remain, as highlighted by mixed results in recent clinical trials.➢ The future of OA management lies in precision molecular orthopaedics: matching patients to targeted therapies on the basis of their predominant disease endotype.